Vaxcyte launches public offering of stock, warrants
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
86,000€
2,08%
Echtzeit-Aktienkurs Vaxcyte Inc.
Bid:
Ask:
Nachrichten zur Vaxcyte Inc. Aktie
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
SAN CARLOS, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company…
Vaxcyte climbs 70% after pneumococcal vaccine data
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Vaxcyte, Motus lead healthcare gainers; Tricida, Accelerate Diagnostics top losers
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Thinking about buying stock in Vaxcyte, Frontline, Avis Budget Group, ServiceNow, or Wolfspeed?
NEW YORK, Oct. 24, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PCVX, FRO, CAR, NOW, and WOLF. To…
Vaxcyte Shares Surge on Positive Trial Data for Pneumococcal Vaccine
Vaxcyte Shares Surge on Positive Trial Data for Pneumococcal Vaccine...…
Form 8-K Vaxcyte, Inc. For: Oct 24
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Vaxcytes stock rallies 46% on positive data for its pneumococcal vaccine candidate
Shares of Vaxcyte Inc. soared 46.7% in premarket trading on Monday after the company said its experimental 24-valent pneumococcal…
Vaxcyte climbs 38% after proof-of-concept data for pneumococcal vaccine
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64
-- In the Study, VAX-24 Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20™ (PCV20) at All Doses Studied…
Vaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults
SAN CARLOS, Calif., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company…
Insiderhandel: VP, Research verkauft Aktien von Vaxcyte Inc im Wert von 127.500$
Fairman, Jeff - Vorstand - Tag der Transaktion: 2022-10-11...…
Vaxcyte appoints new CBO, CMO
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Vaxcyte Expands Executive Leadership Team with Key Appointments
-- Vaxcyte has Appointed Mark Wiggins, M.B.A. as Chief Business Officer and Jakub Simon M.D., M.S. as Chief Medical Officer…